Pre-clinical studies have described that treatment with STING agonists can induce an increase in the abundance and functionality of tumor-infiltrating cytotoxic T cells associated with tumor regression (135–137) and STING stimulation has also been shown to antagonize expansion of immune suppressive myeloid derived suppressor cells (138). The gene discussed is STING1; the disease is neoplasm.